<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02589548</url>
  </required_header>
  <id_info>
    <org_study_id>RBLH</org_study_id>
    <nct_id>NCT02589548</nct_id>
  </id_info>
  <brief_title>Brazilian Prospective Hodgkin Lymphoma Registry</brief_title>
  <official_title>Brazilian Prospective Hodgkin Lymphoma Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective registry of Hodgkin Lymphoma (HL) patients in Brazil.&#xD;
&#xD;
      The purpose of the study is to gather clinical, epidemiologic and outcomes data on the&#xD;
      treatment of HL, on the basis of records collected by key Brazilian institutions, through a&#xD;
      centralized web-based registry of clinical data verified by central board of&#xD;
      hematopathologists.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hodgkin Lymphoma is considered one of the malignancies with highest cure rates. Its prognosis&#xD;
      improved substantially along the last three decades, as a result of relevant cooperative&#xD;
      studies carried out in American and European institutions. Around 70-80% of the patients are&#xD;
      cured with the available chemotherapy regimens.&#xD;
&#xD;
      However, data about HL in developing countries are scarce. It is well established that&#xD;
      patients in underprivileged societies present with malignancies in more advanced stages. In&#xD;
      studies of HL patients treated in Brazil during the 80's, most patients presented with&#xD;
      advanced disease.&#xD;
&#xD;
      The creation of registry of patients with HL will provide a more reliable picture of the&#xD;
      disease in the country, its prevalence in different areas and socioeconomic groups, and&#xD;
      treatment outcomes. It will also foster the establishment of a network among hospitals in all&#xD;
      regions of the country, which may serve as a platform for further development of cooperative&#xD;
      studies engaging the main Brazilian Institutions.&#xD;
&#xD;
      The data collection allows comparison of data entered into the registry against predefined&#xD;
      rules for range or consistency with other data fields in the registry. Also, quality&#xD;
      assurance addresses data validation and data analysis. Standard descriptive analyses will be&#xD;
      carried out. For a crude association analysis, categorical data will be analysed using the&#xD;
      chi-square or Fisher's exact test (two-sided). Survival curves will be estimated using the&#xD;
      Kaplan-Meier method and compare using the log-rank test. Univariate and multivariate Cox&#xD;
      regression analyses will be conducted to verify the prognostic factors regarding Progression&#xD;
      free survival and Overall survival, adjusted for relevant prognostic clinical variables and&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Event free survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Hodgkin Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Formalin-fixed tissue for central diagnostic pathology review&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hodgkin Lymphoma patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously untreated HL patients&#xD;
&#xD;
          -  Clinical data including baseline information on disease localization and laboratory&#xD;
             parameters at staging, features of treatment adopted and assurance of follow-up&#xD;
             updating for at least 5 years are requested&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelson Spector, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UFRJ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irene Biasoli</last_name>
    <role>Principal Investigator</role>
    <affiliation>UFRJ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nelson Spector, MD</last_name>
    <phone>+552139382460</phone>
    <email>spector@ufrj.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irene Biasoli, MD</last_name>
    <phone>+552139382460</phone>
    <email>irene.biasoli@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidade Federal Do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IRENE BIASOLI, MD</last_name>
      <phone>552139382460</phone>
      <email>irene.biasoli@gmail.com</email>
    </contact>
    <investigator>
      <last_name>NELSON CASTRO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARCIA DELAMAIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>RAFAEL GAIOLLA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BELINDA SIMÃ•ES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CRISTIANA SOLZA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CARLOS CHIATTONE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CAROLINE BONAMIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>NELMA CLEMENTINO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MONICA PRAXEDES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CARLA BOQUIMPANI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>OTAVIO BAIOCCHI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>JAMES FARLEY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CARMINO DE SOUZA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>KATIA PAGNANO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Irene Biasoli</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hodgkin Lymphoma</keyword>
  <keyword>Hodgkin Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

